1-3 of 3
Anne Keating
Close
Sort by
Journal Articles

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

Jing Chen, Cynthia A. Pise-Masison, Joanna H. Shih, John C. Morris, John E. Janik, Kevin C. Conlon, Anne Keating, Thomas A. Waldmann
Journal: Blood
Blood (2013) 121 (11): 2029–2037.
https://doi.org/10.1182/blood-2012-05-427773
Published: 2013
Includes: Supplemental data
Journal Articles

A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible for or Have Previously Received an Autologous Stem Cell Transplant - Stage I Results.

Kyriakos P Papadopoulos, MD, Scott E. Smith, MD, PhD, Joyce Steinberg, MD, Renelle Papa, Javier Lopez-Jimenez, MD, Anne Keating, PharmD, Antoine Thyss
Journal: Blood
Blood (2012) 120 (21): 2731.
https://doi.org/10.1182/blood.V120.21.2731.2731
Published: 2012
Journal Articles

Efficacy and Safety of YM155 in Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients Enrolled in a Phase I Study.

Kyriakos Papadopoulos, MD, Alain Mita, MD, Scott Antonio, MD, Lionel D. Lewis, MD, N.J. Reddy, Elizabeth Till, J.J. Mahany, Anne Keating, DPharm, Amanda Seiz, Pamela Bartels, Anthony Tolcher, MD
Journal: Blood
Blood (2007) 110 (11): 3422.
https://doi.org/10.1182/blood.V110.11.3422.3422
Published: 2007